Trained AthletesTULiPNCT07897357
Trained vs. Untrained: Lower Extremity Pressure Changes
A study testing Lower body positive and negative pressure in people with Trained Athletes and Untrained, run by University of Alberta at 1 site in Canada.
Trial summary
Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Trained Athletes, Untrained
- What is being tested?
- Lower body positive and negative pressure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- 9 Oct 2026to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18-40 years old.
Who cannot join
- Severe obesity (body mass index >35 kg/m2).
- Self-reported blood donation or transfusion in the past 60 days. Large artificial fluctuations in blood volume may impact the findings of the present study.
- Pregnancy. To confirm this, women not using contraception will be given a pregnancy test. Pregnancy presents additional complications and may confound the results of the study; therefore, pregnant women will be excluded.
- Known chronic disease (heart failure, hypertension, diabetes, asthma, chronic obstructive pulmonary disease, renal disease).
- Participants with known postural orthostatic tachycardic syndrome or orthostatic hypotension.
- Participants who currently smoke cigarettes (within the last month) or those who have >1 pack-year smoking history.
- Participants who currently smoke cannabis products (within the last month) or those who have >1 joint-year cannabis history.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Clinical Physiology Laboratory
Edmonton, Alberta, T6G 2R3
Desi P Fuhr, MSc, 780-492-1121, fuhr@ualberta.ca
Michael K Stickland, PhD, 780-492-3995, michael.stickland@ualberta.ca
About this study
Official title: Central Blood Volume Shifts in Healthy Adults With Varying Levels of Fitness: Effects on Lung Diffusing Capacity
Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. The exact reasons for these differences are still unclear. This study will test one possible explanation: highly trained people may handle changes in the amount of blood returning to the heart differently than people who are not trained. We want to learn how the blood vessels in the lungs react when the amount of blood entering the heart changes, and how this reaction is affected by fitness level. To do this, we will change how much blood returns to the heart by applying air pressure around the legs, similar to a light vacuum. These changes are expected to be similar to what happens when someone moves from lying down to standing up.
Read the detailed description
Purpose and hypothesis
The purpose of the current study is to determine the impact of endurance training status and biological sex on pulmonary diffusing capacity for carbon monoxide (DLCO) and its components (pulmonary capillary blood volume [Vc] and pulmonary membrane diffusing capacity [Dm]) during acute changes in central blood volume using varying levels of lower body positive and negative pressure (LBPP and LBNP) and head down and head up tilt (HDT and HUT).
The investigators hypothesize that for a given reduction (i.e., LBNP, HUT) or increase (i.e., LBPP, HDT) in central blood volume, endurance-trained individuals will demonstrate greater changes in DLCO compared to untrained individuals. As a second exploratory aim, the investigators hypothesize that females will have larger changes in DLCO compared to males.
Research Method/Procedures
All visits will happen on separate days with at least 24 hours between visits. All visits will take place within 4 months.
Visit 1: Screening
On the screening day, the participant will complete the informed consent procedure, fill out a medical history form, and be screened for exercise using the modified medical research council (mMRC) dyspnea scale, PAR-Q+ exercise readiness questionnaire and the Physical Activity and Sedentary Behaviour Questionnaire (PASB-Q). The investigators will then perform pulmonary function tests on each participant. Finally, the participant will complete a graded exercise test on an upright cycle ergometer to volitional exhaustion to determine maximal oxygen consumption (V̇O2max). Evaluation of dyspnea including intensity and unpleasantness will be performed at each workload. Further, reasons for test termination, dyspnea, and qualitative descriptors of dyspnea will be evaluated at peak exercise. Hemoglobin concentration will be measured via finger prick prior to and following completion of exercise testing.
Visit 2: Central Blood Volume Manipulation and DLCO
The participant will perform the DLCO test at various levels of LBNP/LBPP ranging from -80 mmHg to +40 mmHg, or HUT/HDT ranging between 90° and -12°. Head tilt and lower body pressure changes provide a similar intervention that can be used interchangeably based on equipment availability. Changes in central blood volume during LBNP/HUT are equivalent to standing upright (-80 mmHg LBNP or 90° HUT), and changes in central blood volume during LBPP/HDT are equivalent to someone lying down with their feet above their head (+40 mmHg LBPP or -12° HDT). For the LBNP/LBPP trials, participants will lay supine with their lower body (from the iliac crest to their toes) inside the pressure chamber. The participant's lower body will be sealed within the differential pressure chamber using a neoprene skirt to prevent any air leakage from the insides of the chamber. Negative and positive pressures are induced by a vacuum pump that either reduces or increases pressure inside the chamber in a controlled and precise manner. The vacuum pump is controlled by a trained member of the research team, and chamber pressure is continuously monitored via a digital manometer. For the HUT/HDT trials, the participant will lie supine on a tilt table. The table will be electronically adjusted to the desired angle at a rate of 1°/second.
Once participants are secured in the lower body pressure chamber or on the tilt table, a certified technician will insert an intravenous (IV) catheter into an antecubital vein which will allow peripheral venous pressure measurements. Participants will also be equipped with a continuous blood pressure monitor, a brachial blood pressure cuff, an electrocardiogram, and a thoracic impedance device. Each stage of LBPP/LBNP or HUT/HDT will begin with two minutes of stabilization followed by two DLCO breath-hold maneuvers. At each stage participants will also breathe on a mouthpiece for two minutes to collect metabolic data: ventilation (V̇E), oxygen consumption (V̇O2), and carbon dioxide production (V̇CO2). Cardiovascular parameters (blood pressure, peripheral venous pressure, heart rate, thoracic impedance) will be measured continuously. Hemoglobin will be measured at each stage via a small (< 1 mL) blood sample from the IV. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from the IV for sex hormone analyses.
Participants will not complete more than 15 DLCO breath holds during each experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. A washout period of at least 4 minutes between each breath hold will be completed to ensure adequate recovery and blood gas equilibration.
Visit 3: DLCO with Exercise
Exercise will be used as a physiological stressor to increase central blood volume beyond that of LBPP or HDT. The participant will perform the DLCO maneuvers during exercise at varying exercise intensities (~20%-100% of an individual's V̇O2max). Participants will not complete more than 15 breath holds during the experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. At each exercise intensity, participants will breathe on a mouthpiece for two minutes to collect metabolic data; heart rate and peripheral oxygen saturation will be measured continuously for the same two minutes at each intensity. Blood pressure will be measured once per stage with an automatic sphygmomanometer. Hemoglobin via finger prick will also be measured at each intensity. A washout period of at least 2 minutes between each breath hold during exercise will be completed to ensure adequate recovery and blood gas equilibration. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from an antecubital vein for sex hormone analyses.
Visit 4: Ultrasound with LBNP/HUT, LBPP/ HDT, and Exercise
Participants will complete the same interventions as visit 2 (LBNP/LBPP -80 to +40 mmHg, or HUT/HDT 90° to -12°) and visit 3 (exercise at ~20%-100% of an individual's V̇O2max). At each stage of LBNP/LBPP or HUT/HDT, and exercise, a trained sonographer will obtain images of the heart via echocardiography. Participants will then undergo a carbon monoxide rebreathe protocol to estimate blood volume. A certified technician will insert an IV catheter into an antecubital vein to collect serial blood samples. While lying supine, participants will inhale a bolus of carbon monoxide (0.7-1.0 mL/kg bodyweight) mixed with 100% oxygen on a rebreathing circuit for two minutes and will then continue to rest for eight additional minutes. Venous blood samples measuring carboxyhemoglobin before the rebreathe and eight minutes after the rebreathe will allow the calculation of blood volume.
Visit 5: Computed Tomography
Participants will report to a Medical Imaging Centre for the computed tomography (CT) scan. Following a briefing by the Medical Imaging Centre staff, participants will lay supine on the CT scanner and the region of interest in the chest will be obtained. The participant will remain as still as possible and inhale to total lung capacity and hold their breath. During the breath hold, images will be acquired. The participant will then empty their lungs as far as they can and imaging will be repeated.
CT can noninvasively detect features of pulmonary vascular dysfunction. CT outcomes-such as pulmonary artery diameter, vessel pruning, perfusion heterogeneity, and right ventricular morphology-correlate with hemodynamic abnormalities and impaired pulmonary vascular reserve. These imaging biomarkers enable early identification and monitoring of pulmonary vascular disease, providing clinically relevant information beyond conventional structural assessment. In healthy individuals, CT can provide valuable information characterizing pulmonary structure not available using other non-invasive techniques. For example, CT can provide quantitative information on pulmonary vascular and airway branching to show potential structural differences inherent to highly fit individuals. CT is therefore a tool to characterize differences in lung structure which may also potentially explain differences in lung function elucidated by the other measures in this study.
- Conditions
- Trained Athletes, Untrained
- Being tested
- Lower body positive and negative pressure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lower body positive and negative pressureOther
Graded lower body positive pressure (+10, +20, +30 mmHg) and negative pressure (-15, -30, -45, -60 mmHg).
| Study group | Role | What they receive |
|---|---|---|
| All participants | Experimental | All participants complete all five visits as outlined in the study description. Receives: Other: Lower body positive and negative pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in diffusing capacity for carbon monoxide (DLCO)
Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Change in capillary blood volume (Vc)
Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Change in membrane diffusing capacity (Dm)
Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Measured: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2026
- Study start9 Oct 2026 (estimated)
- Primary completion15 Dec 2027 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Trained AthletesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael K Stickland, PhD, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07897357
- Sponsor's protocol ID
- Pro00160257
- Acronym
- TULiP
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Brotto AR, de Waal S, D'Souza AW, Beaudry RI, Ehnes CM, Collins SE, Fuhr DP, van Diepen S, Stickland MK. Impact of body posture on pulmonary diffusing capacity at rest and during exercise in endurance-trained and untrained individuals. J Appl Physiol (1985). 2025 Jan 1;138(1):301-310. doi: 10.1152/japplphysiol.00447.2024. Epub 2024 Dec 16.
PubMed 39681333Tedjasaputra V, Bouwsema MM, Stickland MK. Effect of aerobic fitness on capillary blood volume and diffusing membrane capacity responses to exercise. J Physiol. 2016 Aug 1;594(15):4359-70. doi: 10.1113/JP272037. Epub 2016 May 12.
PubMed 26959808Shi X, Crandall CG, Raven PB. Hemodynamic responses to graded lower body positive pressure. Am J Physiol. 1993 Jul;265(1 Pt 2):H69-73. doi: 10.1152/ajpheart.1993.265.1.H69.
PubMed 8342666Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol. 2012 Sep 1;590(17):4279-88. doi: 10.1113/jphysiol.2012.234310. Epub 2012 Jun 25.
PubMed 22733662
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Central Blood Volume Shifts in Healthy Adults With Varying Levels of Fitness: Effects on Lung Diffusing Capacity
- ClinicalTrials.gov ID
- NCT07897357
- Acronym / sponsor ID
- TULiP / Pro00160257
- Conditions
- Trained Athletes, Untrained
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 9 Oct 2026 (estimated)
- Primary completion
- 15 Dec 2027 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 27 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. The exact reasons for these differences are still unclear. This study will test one possible explanation: highly trained people may handle changes in the amount of blood returning to the heart differently than people who are not trained. We want to learn how the blood vessels in the lungs react when the amount of blood entering the heart changes, and how this reaction is affected by fitness level. To do this, we will change how much blood returns to the heart by applying air pressure around the legs, similar to a light vacuum. These changes are expected to be similar to what happens when someone moves from lying down to standing up.
Detailed description
Purpose and hypothesis
The purpose of the current study is to determine the impact of endurance training status and biological sex on pulmonary diffusing capacity for carbon monoxide (DLCO) and its components (pulmonary capillary blood volume [Vc] and pulmonary membrane diffusing capacity [Dm]) during acute changes in central blood volume using varying levels of lower body positive and negative pressure (LBPP and LBNP) and head down and head up tilt (HDT and HUT).
The investigators hypothesize that for a given reduction (i.e., LBNP, HUT) or increase (i.e., LBPP, HDT) in central blood volume, endurance-trained individuals will demonstrate greater changes in DLCO compared to untrained individuals. As a second exploratory aim, the investigators hypothesize that females will have larger changes in DLCO compared to males.
Research Method/Procedures
All visits will happen on separate days with at least 24 hours between visits. All visits will take place within 4 months.
Visit 1: Screening
On the screening day, the participant will complete the informed consent procedure, fill out a medical history form, and be screened for exercise using the modified medical research council (mMRC) dyspnea scale, PAR-Q+ exercise readiness questionnaire and the Physical Activity and Sedentary Behaviour Questionnaire (PASB-Q). The investigators will then perform pulmonary function tests on each participant. Finally, the participant will complete a graded exercise test on an upright cycle ergometer to volitional exhaustion to determine maximal oxygen consumption (V̇O2max). Evaluation of dyspnea including intensity and unpleasantness will be performed at each workload. Further, reasons for test termination, dyspnea, and qualitative descriptors of dyspnea will be evaluated at peak exercise. Hemoglobin concentration will be measured via finger prick prior to and following completion of exercise testing.
Visit 2: Central Blood Volume Manipulation and DLCO
The participant will perform the DLCO test at various levels of LBNP/LBPP ranging from -80 mmHg to +40 mmHg, or HUT/HDT ranging between 90° and -12°. Head tilt and lower body pressure changes provide a similar intervention that can be used interchangeably based on equipment availability. Changes in central blood volume during LBNP/HUT are equivalent to standing upright (-80 mmHg LBNP or 90° HUT), and changes in central blood volume during LBPP/HDT are equivalent to someone lying down with their feet above their head (+40 mmHg LBPP or -12° HDT). For the LBNP/LBPP trials, participants will lay supine with their lower body (from the iliac crest to their toes) inside the pressure chamber. The participant's lower body will be sealed within the differential pressure chamber using a neoprene skirt to prevent any air leakage from the insides of the chamber. Negative and positive pressures are induced by a vacuum pump that either reduces or increases pressure inside the chamber in a controlled and precise manner. The vacuum pump is controlled by a trained member of the research team, and chamber pressure is continuously monitored via a digital manometer. For the HUT/HDT trials, the participant will lie supine on a tilt table. The table will be electronically adjusted to the desired angle at a rate of 1°/second.
Once participants are secured in the lower body pressure chamber or on the tilt table, a certified technician will insert an intravenous (IV) catheter into an antecubital vein which will allow peripheral venous pressure measurements. Participants will also be equipped with a continuous blood pressure monitor, a brachial blood pressure cuff, an electrocardiogram, and a thoracic impedance device. Each stage of LBPP/LBNP or HUT/HDT will begin with two minutes of stabilization followed by two DLCO breath-hold maneuvers. At each stage participants will also breathe on a mouthpiece for two minutes to collect metabolic data: ventilation (V̇E), oxygen consumption (V̇O2), and carbon dioxide production (V̇CO2). Cardiovascular parameters (blood pressure, peripheral venous pressure, heart rate, thoracic impedance) will be measured continuously. Hemoglobin will be measured at each stage via a small (< 1 mL) blood sample from the IV. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from the IV for sex hormone analyses.
Participants will not complete more than 15 DLCO breath holds during each experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. A washout period of at least 4 minutes between each breath hold will be completed to ensure adequate recovery and blood gas equilibration.
Visit 3: DLCO with Exercise
Exercise will be used as a physiological stressor to increase central blood volume beyond that of LBPP or HDT. The participant will perform the DLCO maneuvers during exercise at varying exercise intensities (~20%-100% of an individual's V̇O2max). Participants will not complete more than 15 breath holds during the experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. At each exercise intensity, participants will breathe on a mouthpiece for two minutes to collect metabolic data; heart rate and peripheral oxygen saturation will be measured continuously for the same two minutes at each intensity. Blood pressure will be measured once per stage with an automatic sphygmomanometer. Hemoglobin via finger prick will also be measured at each intensity. A washout period of at least 2 minutes between each breath hold during exercise will be completed to ensure adequate recovery and blood gas equilibration. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from an antecubital vein for sex hormone analyses.
Visit 4: Ultrasound with LBNP/HUT, LBPP/ HDT, and Exercise
Participants will complete the same interventions as visit 2 (LBNP/LBPP -80 to +40 mmHg, or HUT/HDT 90° to -12°) and visit 3 (exercise at ~20%-100% of an individual's V̇O2max). At each stage of LBNP/LBPP or HUT/HDT, and exercise, a trained sonographer will obtain images of the heart via echocardiography. Participants will then undergo a carbon monoxide rebreathe protocol to estimate blood volume. A certified technician will insert an IV catheter into an antecubital vein to collect serial blood samples. While lying supine, participants will inhale a bolus of carbon monoxide (0.7-1.0 mL/kg bodyweight) mixed with 100% oxygen on a rebreathing circuit for two minutes and will then continue to rest for eight additional minutes. Venous blood samples measuring carboxyhemoglobin before the rebreathe and eight minutes after the rebreathe will allow the calculation of blood volume.
Visit 5: Computed Tomography
Participants will report to a Medical Imaging Centre for the computed tomography (CT) scan. Following a briefing by the Medical Imaging Centre staff, participants will lay supine on the CT scanner and the region of interest in the chest will be obtained. The participant will remain as still as possible and inhale to total lung capacity and hold their breath. During the breath hold, images will be acquired. The participant will then empty their lungs as far as they can and imaging will be repeated.
CT can noninvasively detect features of pulmonary vascular dysfunction. CT outcomes-such as pulmonary artery diameter, vessel pruning, perfusion heterogeneity, and right ventricular morphology-correlate with hemodynamic abnormalities and impaired pulmonary vascular reserve. These imaging biomarkers enable early identification and monitoring of pulmonary vascular disease, providing clinically relevant information beyond conventional structural assessment. In healthy individuals, CT can provide valuable information characterizing pulmonary structure not available using other non-invasive techniques. For example, CT can provide quantitative information on pulmonary vascular and airway branching to show potential structural differences inherent to highly fit individuals. CT is therefore a tool to characterize differences in lung structure which may also potentially explain differences in lung function elucidated by the other measures in this study.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All participants | Experimental | Other: Lower body positive and negative pressureAll participants complete all five visits as outlined in the study description. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- 18-40 years old.
Key exclusion criteria (7 listed)
- Severe obesity (body mass index >35 kg/m2).
- Self-reported blood donation or transfusion in the past 60 days. Large artificial fluctuations in blood volume may impact the findings of the present study.
- Pregnancy. To confirm this, women not using contraception will be given a pregnancy test. Pregnancy presents additional complications and may confound the results of the study; therefore, pregnant women will be excluded.
- Known chronic disease (heart failure, hypertension, diabetes, asthma, chronic obstructive pulmonary disease, renal disease).
- Participants with known postural orthostatic tachycardic syndrome or orthostatic hypotension.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lower body positive and negative pressureGraded lower body positive pressure (+10, +20, +30 mmHg) and negative pressure (-15, -30, -45, -60 mmHg). | Other | All participants |
Primary outcome
Change in diffusing capacity for carbon monoxide (DLCO)
Time frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Change in capillary blood volume (Vc)
Time frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Change in membrane diffusing capacity (Dm)
Time frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Background: PubMed 39681333Brotto AR, de Waal S, D'Souza AW, Beaudry RI, Ehnes CM, Collins SE, Fuhr DP, van Diepen S, Stickland MK. Impact of body posture on pulmonary diffusing capacity at rest and during exercise in endurance-trained and untrained individuals. J Appl Physiol (1985). 2025 Jan 1;138(1):301-310. doi: 10.1152/japplphysiol.00447.2024. Epub 2024 Dec 16.
- Background: PubMed 26959808Tedjasaputra V, Bouwsema MM, Stickland MK. Effect of aerobic fitness on capillary blood volume and diffusing membrane capacity responses to exercise. J Physiol. 2016 Aug 1;594(15):4359-70. doi: 10.1113/JP272037. Epub 2016 May 12.
- Background: PubMed 8342666Shi X, Crandall CG, Raven PB. Hemodynamic responses to graded lower body positive pressure. Am J Physiol. 1993 Jul;265(1 Pt 2):H69-73. doi: 10.1152/ajpheart.1993.265.1.H69.
- Background: PubMed 22733662Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol. 2012 Sep 1;590(17):4279-88. doi: 10.1113/jphysiol.2012.234310. Epub 2012 Jun 25.
- Individual participant dataSharing planned: Undecided
Related trials for Trained Athletes
Active, not recruiting
Effects of Short-term Adaptation to Ketogenic Diet on Endurance Trained Athletes
Ketogenic Diet, Control Condition
Not yet recruiting
The Effects of Acute Nitrate and Caffeine Co-ingestion on Discipline-Specific Exercise Performance.
Athletic Performance, Dietary Supplement
RecruitingPhase 3
Acute Sodium Bicarbonate Supplementation in Female Basketball Players
Supplementation, Sports
Not yet recruiting
Beetroot Beverage and Repeated Sprint Power Output During RAST
Repeated Sprint Performance in Trained Athletes, Exercise Performance
RecruitingObservational study
Physiological and Biochemical Responses to Blood Flow Restriction Training
Healthy Individuals, Trained Athletes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Michael K Stickland, PhD principal investigator
University of Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lower body positive and negative pressure in people with Trained Athletes and Untrained, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Desi P Fuhr, MSc (780-492-1121, fuhr@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in diffusing capacity for carbon monoxide (DLCO) (time frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07897357, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.